Free Trial

ValiRx (VAL) Competitors

ValiRx logo
GBX 0.61 +0.01 (+2.00%)
As of 08/1/2025 12:17 PM Eastern

VAL vs. NOG, HNR, SUN, EOG, WRES, EQT, CRC, WEB, NBL, and FTO

Should you be buying ValiRx stock or one of its competitors? The main competitors of ValiRx include Nostrum Oil & Gas (NOG), Highlands Natural Resources (HNR), Surgical Innovations Group (SUN), Europa Oil & Gas (EOG), W Resources (WRES), EQTEC (EQT), Circle Property (CRC), Webis (WEB), 18564 (NBL.L) (NBL), and 2059984 (FTO.L) (FTO). These companies are all part of the "petroleum and natural gas" industry.

ValiRx vs. Its Competitors

ValiRx (LON:VAL) and Nostrum Oil & Gas (LON:NOG) are both small-cap petroleum and natural gas companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

In the previous week, Nostrum Oil & Gas had 2 more articles in the media than ValiRx. MarketBeat recorded 3 mentions for Nostrum Oil & Gas and 1 mentions for ValiRx. ValiRx's average media sentiment score of -0.20 beat Nostrum Oil & Gas' score of -0.30 indicating that ValiRx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ValiRx
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nostrum Oil & Gas
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

ValiRx has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Nostrum Oil & Gas has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Nostrum Oil & Gas has a consensus target price of GBX 4, indicating a potential upside of 1.52%. Given Nostrum Oil & Gas' stronger consensus rating and higher probable upside, analysts plainly believe Nostrum Oil & Gas is more favorable than ValiRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ValiRx
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nostrum Oil & Gas
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nostrum Oil & Gas has a net margin of -59.05% compared to ValiRx's net margin of -20,554.01%. Nostrum Oil & Gas' return on equity of 74.84% beat ValiRx's return on equity.

Company Net Margins Return on Equity Return on Assets
ValiRx-20,554.01% -55.84% -35.98%
Nostrum Oil & Gas -59.05%74.84%1.53%

22.3% of Nostrum Oil & Gas shares are owned by institutional investors. 18.3% of ValiRx shares are owned by company insiders. Comparatively, 44.3% of Nostrum Oil & Gas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ValiRx has higher earnings, but lower revenue than Nostrum Oil & Gas. ValiRx is trading at a lower price-to-earnings ratio than Nostrum Oil & Gas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ValiRx£27.78K83.64-£5.71M-£1.48-0.41
Nostrum Oil & Gas£206.12M0.05-£121.71M-£29.66-0.13

Summary

Nostrum Oil & Gas beats ValiRx on 11 of the 15 factors compared between the two stocks.

Get ValiRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VAL vs. The Competition

MetricValiRxBiotechnology IndustryMedical SectorLON Exchange
Market Cap£2.32M£134.75M£5.52B£3.03B
Dividend Yield0.63%3.74%4.74%5.02%
P/E Ratio-0.413.8028.93176.75
Price / Sales83.644,246.60440.51264,362.45
Price / Cash62.5013.1935.0727.97
Price / Book0.2339.388.254.53
Net Income-£5.71M-£90.99M£3.25B£5.90B
7 Day Performance-4.23%-2.02%-3.75%12.58%
1 Month Performance9.29%3.61%2.99%4.67%
1 Year Performance-78.14%186.14%25.35%72.88%

ValiRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VAL
ValiRx
N/AGBX 0.61
+2.0%
N/A-78.1%£2.32M£27.78K-0.415,450Gap Down
NOG
Nostrum Oil & Gas
0.4498 of 5 stars
GBX 3
-12.3%
GBX 6
+100.0%
-25.1%£7.90M£206.12M-0.1030News Coverage
Analyst Forecast
Gap Down
HNR
Highlands Natural Resources
N/AN/AN/AN/A£6.95M£1.02M-0.9616Gap Down
High Trading Volume
SUN
Surgical Innovations Group
N/AGBX 0.66
-6.4%
N/A-0.6%£6.11M£12.54M-21.1180Gap Down
EOG
Europa Oil & Gas
N/AGBX 0.52
+9.3%
N/A-52.4%£4.98M£3.57M-0.732,850Gap Up
WRES
W Resources
N/AN/AN/AN/A£3.89M£3.47M-0.4366Gap Down
EQT
EQTEC
N/AGBX 0.50
-3.7%
N/A-58.2%£1.29M£3.85M-2.95740Gap Up
CRC
Circle Property
N/AN/AN/AN/A£1.02M£7.57M50.001,060Gap Down
High Trading Volume
WEB
Webis
N/AN/AN/AN/A£157K£49.70M14.1350Gap Down
NBL
18564 (NBL.L)
N/AN/AN/AN/A£0.00N/A0.002,330
FTO
2059984 (FTO.L)
N/AN/AN/AN/A£0.00N/A0.00147,000

Related Companies and Tools


This page (LON:VAL) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners